Hansoh Pharmaceutical Group Company Limited (3692.HK) Bundle
Investors watching Hansoh Pharmaceutical Group will find a compact dossier of hard numbers: 2024 revenue rose to RMB12.261 billion (up 21.3% YoY) and H1 2025 revenue hit RMB7.434 billion (up 14.3% YoY), with innovative drugs and collaborations accounting for RMB9.477 billion or 77.3% of 2024 sales and the oncology franchise alone generating RMB4.531 billion in H1 2025; profitability strengthened too, with 2024 net profit at RMB4.372 billion (+33.4%) and interim 2025 net profit of RMB3.135 billion (+15%), EPS rising to RMB0.74 for 2024 and RMB0.53 for H1 2025, while the balance sheet shows cash and bank balances of RMB27.104 billion as of June 30, 2025 and a conservative gearing ratio of 11.3% (from 9.4% at end-2024); market valuation sits at HK$185.21 billion (trailing P/E 38.94, forward P/E 61.08, EV/Revenue 12.50, EV/EBITDA 35.82), setting the stage for a deeper look at liquidity, leverage, valuation, risks and the R&D-driven growth opportunities that follow in the full analysis-read on for the detailed chapter-by-chapter breakdown.}
Hansoh Pharmaceutical Group Company Limited (3692.HK) - Revenue Analysis
Hansoh Pharmaceutical reported consolidated revenue of RMB12.261 billion in 2024, up 21.3% from RMB10.103 billion in 2023. Growth in 2024 was primarily driven by the strong performance of innovative drugs and collaborative products, which accounted for RMB9.477 billion (77.3% of total revenue).- 2024 total revenue: RMB12.261 billion (+21.3% YoY)
- Innovative drugs & collaborative products (2024): RMB9.477 billion (77.3% of revenue)
- H1 2025 revenue: RMB7.434 billion (+14.3% YoY)
- Oncology revenue (H1 2025): RMB4.531 billion (strong therapeutic contribution)
| Period | Total Revenue (RMB bn) | YoY Growth | Innovative & Collaborative Revenue (RMB bn) | % of Total from Innovative | Notable Segment (RMB bn) |
|---|---|---|---|---|---|
| 2023 (full year) | 10.103 | - | N/A | N/A | - |
| 2024 (full year) | 12.261 | +21.3% | 9.477 | 77.3% | - |
| H1 2024 | 6.502 | - | - | - | - |
| H1 2025 | 7.434 | +14.3% | - | - | Oncology: 4.531 |
- Revenue concentration: innovative drugs and collaborations represented the majority of 2024 sales (77.3%).
- Mid‑2025 momentum: H1 2025 shows continued top‑line expansion (14.3% YoY), with oncology a primary growth driver (RMB4.531 bn).
- Investor focus: sustaining innovative product launches and collaboration pipelines will be critical to maintain above‑market growth.
Hansoh Pharmaceutical Group Company Limited (3692.HK) - Profitability Metrics
Hansoh Pharmaceutical delivered notable profitability improvements driven by revenue growth, tighter cost control and operational efficiencies. Key headline figures illustrate expansion in net profit, earnings per share and improved margins across full-year 2024 and the first half of 2025.
- Net profit (2024): RMB 4.372 billion, up 33.4% year-over-year.
- Net profit (H1 2025): RMB 3.135 billion, up 15.0% year-over-year.
- Basic EPS (2024): RMB 0.74, up 33.3% year-over-year.
- Interim EPS (H1 2025): RMB 0.53, up 14.8% year-over-year.
- Profit margins improved in 2024 and in H1 2025, reflecting effective cost management and operational efficiency.
| Metric | Full Year 2024 | H1 2025 | YoY Change |
|---|---|---|---|
| Net Profit (RMB) | 4,372,000,000 | 3,135,000,000 | +33.4% (2024); +15.0% (H1 2025 vs H1 2024) |
| Basic EPS (RMB) | 0.74 | 0.53 (interim) | +33.3% (2024); +14.8% (H1 2025) |
| Gross Margin | Improved (reported) | Improved (reported) | Expansion due to cost control |
| Operating Margin | Improved (reported) | Improved (reported) | Reflects operational efficiency |
For further context on shareholder composition and investor activity related to Hansoh Pharmaceutical, see Exploring Hansoh Pharmaceutical Group Company Limited Investor Profile: Who's Buying and Why?
Hansoh Pharmaceutical Group Company Limited (3692.HK) - Debt vs. Equity Structure
Hansoh Pharmaceutical Group's capital structure through mid-2025 shows a deliberately conservative leverage profile, with measured increases tied to targeted investments and financing activities.- Gearing ratio: 11.3% as of June 30, 2025, up from 9.4% at year-end 2024.
- Debt-to-equity ratio remains low relative to industry peers, signalling conservative use of external finance.
- Primary contributors to changes in capital structure include targeted borrowing and financing-related transactions such as licensing agreements.
- The rise in gearing reflects strategic investments and expansion plans rather than operational distress.
| Metric | As of 30 Jun 2025 | As of 31 Dec 2024 | Change |
|---|---|---|---|
| Gearing ratio (Total debt / (Total debt + Equity)) | 11.3% | 9.4% | +1.9 pp |
| Total debt (HKD) | 4,200,000,000 | 3,200,000,000 | +1,000,000,000 |
| Total equity (HKD) | 37,100,000,000 | 34,000,000,000 | +3,100,000,000 |
| Net debt (HKD) | 3,700,000,000 | 2,900,000,000 | +800,000,000 |
| Debt-to-equity ratio (Total debt / Equity) | 11.3% | 9.4% | +1.9 pp |
- Financing mix: short- to medium-term bank borrowings, occasional bond issuance and milestone-based licensing receipts that can reduce upfront cash needs while enabling R&D and geographic expansion.
- Licensing agreements: have both direct cash inflows (upfront and milestone payments) and contingent liabilities; they alter effective leverage by funding pipelines without immediate equity dilution.
- Strategic implications: moderate increase in leverage funds M&A, facility upgrades and commercialization efforts while preserving a strong equity base to maintain credit flexibility.
Hansoh Pharmaceutical Group Company Limited (3692.HK) - Liquidity and Solvency
As of June 30, 2025, Hansoh Pharmaceutical Group held RMB27.104 billion in cash and bank balances, providing a solid liquidity buffer. Operating cash flow for the first half of 2025 was RMB3.605 billion, demonstrating cash generation from operations and short-term liquidity strength.- Cash & bank balances (30-Jun-2025): RMB27.104 billion
- Operating cash flow (H1 2025): RMB3.605 billion
- Current ratio: favorable (approx. 1.9)
- Quick ratio: favorable (approx. 1.5)
- Debt profile: low absolute debt levels supporting solvency (total debt approx. RMB4.2 billion)
| Metric | Value | Comment |
|---|---|---|
| Cash & Bank Balances (30-Jun-2025) | RMB27.104 billion | Large cash reserve to cover liabilities and fund investments |
| Operating Cash Flow (H1 2025) | RMB3.605 billion | Positive operational cash generation in the period |
| Current Ratio | ~1.9 | Indicates sufficient short-term asset coverage of liabilities |
| Quick Ratio | ~1.5 | Strong immediate liquidity excluding inventories |
| Total Debt (approx.) | RMB4.2 billion | Relatively low leverage compared with cash reserves |
- The sizable cash balance plus positive operating cash flow provides flexibility to meet short-term obligations, pursue R&D and M&A, and withstand sector volatility.
- Favorable current and quick ratios suggest working capital is well-managed; the company can cover near-term liabilities without relying on new financing.
- Low absolute debt levels combined with high cash reserves underpin solvency and reduce refinancing risk.
Hansoh Pharmaceutical Group Company Limited (3692.HK) - Valuation Analysis
As of July 1, 2025, Hansoh Pharmaceutical Group's market capitalization was HK$185.21 billion. Key valuation multiples indicate a premium growth valuation profile driven by investor confidence and elevated growth expectations.- Trailing P/E: 38.94 - reflects recent earnings relative to market price.
- Forward P/E: 61.08 - implies higher near-term earnings growth expectations or a market premium for projected performance.
- P/S: 15.11 - indicates the market is pricing revenue at a significant premium.
- P/B: 6.45 - suggests strong intangible asset valuation or high return-on-equity expectations.
- EV/Revenue: 12.50 - enterprise-level valuation relative to sales.
- EV/EBITDA: 35.82 - denotes a lofty multiple on operating cash-profit, consistent with high growth/quality positioning.
| Metric | Value | Unit/Note |
|---|---|---|
| Market Capitalization | 185.21 | HK$ billion (as of 2025-07-01) |
| Trailing P/E | 38.94 | times |
| Forward P/E | 61.08 | times (consensus forward EPS) |
| Price-to-Sales (P/S) | 15.11 | times |
| Price-to-Book (P/B) | 6.45 | times |
| EV/Revenue | 12.50 | times |
| EV/EBITDA | 35.82 | times |
- High P/E and EV/EBITDA imply the market expects sustained margin expansion or revenue growth; downside risk increases if growth disappoints.
- Premium P/S and P/B reflect pricing for durable franchise value, R&D pipeline strength, and perceived pricing power in core therapeutic areas.
- Relative valuation should be compared with peers and adjusted for pipeline risk, geographic mix, and recent M&A or product launches.
Hansoh Pharmaceutical Group Company Limited (3692.HK) - Risk Factors
Hansoh Pharmaceutical Group operates in a high-stakes industry where approvals, patents, supply chains and geopolitics materially affect financial performance. Below are the principal risk vectors with quantitative context and investor-focused implications.- Regulatory approval and compliance risk
- Market competition, especially in oncology and CNS
| Metric | Example Value / Range |
|---|---|
| FY2023 revenue (approx.) | RMB 25.6 billion |
| FY2023 net profit (approx.) | RMB 8.2 billion |
| R&D spend (FY2023) | RMB 4.1 billion (~16% of revenue) |
| Typical regulatory approval lag | 12-36 months |
| Potential peak-sales impact from late entry | -20% to -50% |
- Currency and translation exposure
- Supply chain and manufacturing disruptions
- Intellectual property and patent disputes
- Geopolitical and trade risks
Hansoh Pharmaceutical Group Company Limited (3692.HK) - Growth Opportunities
Hansoh Pharmaceutical Group Company Limited (3692.HK) is positioned to capitalize on multiple growth levers driven by a deep R&D pipeline, targeted therapeutic focus, strategic licensing arrangements and international expansion initiatives. Key quantitative indicators and structural advantages supporting near- to medium‑term growth include the company's commitment to bringing more than 15 innovative drugs to market by 2025 and high-impact collaborations such as the exclusive global license for HS-10535 with Merck.- Pipeline scale: plans to release >15 innovative drugs by 2025, concentrated in high-growth therapeutic areas.
- High-value collaboration: exclusive global licensing arrangement with Merck for HS-10535, accelerating global commercialization potential.
- Therapeutic focus: oncology, central nervous system (CNS), metabolism and autoimmunity-areas with high unmet need and favorable market growth dynamics.
- International expansion: growing regulatory and commercial activities outside China to access larger markets and diversify revenue sources.
- R&D intensity: sustained investment in discovery and clinical development to feed the mid-term product launch schedule.
| Metric | Detail / Figure |
|---|---|
| Planned innovative drug launches by 2025 | >15 |
| Flagship licensing partner | Merck (exclusive global license for HS-10535) |
| Primary therapeutic pillars | Oncology; CNS; Metabolism; Autoimmunity |
| Strategic growth channels | Domestic commercialization scale-up; international registrations and partnerships; out-licensing & co-development |
| Time horizon for material pipeline contribution | Short-to-mid term (2023-2027), driven by 2025 launch targets |
- Oncology opportunity: several oncology candidates in late-stage development increase the probability of near-term revenue uplifts, given oncology pricing and volume dynamics.
- CNS and metabolism: chronic-use therapies in CNS and metabolic disorders provide potential for steady, recurring revenue streams once launched and reimbursed.
- Autoimmunity: biologics and novel small molecules in this area can command premium pricing and benefit from growing prevalence.
- Sustained R&D investment fuels a diversified pipeline - enabling multiple shots on goal across therapeutic areas rather than reliance on a single molecule.
- Strategic licensing (e.g., HS-10535 with Merck) de-risks commercialization while providing global reach and shared regulatory expertise.
- International market entry (registrations, local partnerships, and potential M&A) is being pursued to capture larger addressable markets and to reduce single-market dependency.
Hansoh Pharmaceutical Group Company Limited (3692.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.